CytoAgents
PrivateLast Round
Grant
Sep 25, 2024
Est. Valuation
$52M
Total Funding Raised
$12.6M
Momentum Score
50 /100
Company Overview
CytoAgents is a biopharmaceutical company that creates innovative drugs aimed at treating cytokine release syndrome, providing accessible solutions for high unmet medical needs across various conditions, including oncology CAR-T cell therapy and respiratory epidemics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CytoAgents Comps
Public and private peers based on sector, stage, and business model.
CytoAgents Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 25, 2024 | ||||
| Series A | May 3, 2023 | ||||
| Grant | Mar 10, 2021 | ||||
| VC Round | Jul 7, 2020 | ||||
| Grant | May 13, 2020 | ||||
Seed | Jun 18, 2019 |
CytoAgents Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pittsburgh Life Sciences Greenhouse | Seed |
| National Cancer Institute | Grant |
| National Institute of Allergy and Infectious Diseases | Grant |
| NIH RADx | Grant |
| Richard King Mellon Foundation | VC Round |
| BlueTree Allied Angels | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors increased 541% MoM, reaching 2.3K.
- Dec 16, 2025
Michael D. Howell appointed as the new Chief Scientific Officer.
CytoAgents Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about CytoAgents's valuation, stock price, and market status.
